| Ablation |
| Acute myeloid leukaemia |
| Adaptive immune system |
| Adverse events |
| Allogeneic stem cell transplantation |
| Alopecia |
| Alternative treatment |
| Anaphylactoid |
| Antibody |
| Anti-CD20 |
| Anticholinergic |
| Antiemetic |
| Antihistamine |
| Antipyretic |
| Antispasticity |
| Apoptosis |
| Astrocyte |
| Asymptomatic |
| Ataxia |
| Atrophy |
| Autoantibodies |
| Autoantigen |
| Autoimmune disease |
| Autologous haematopoietic stem cell transplantation |
| Autonomic nervous system |
| Autoreactive |
| Axon |
| B cell |
| Baseline |
| Benign MS |
| Bradycardia |
| Brain reserve |
| Brainstem |
| Breakthrough disease activity |
| Cancer signal |
| Cannabidiol |
| Capillary leak syndrome |
| Cardiotoxicity |
| CB1 agonists |
| Central nervous system |
| Cerebellar |
| Cerebellum |
| Cerebral cortex |
| Cerebrospinal fluid |
| Cholecystokinin |
| Clinical manifestations |
| Clinically isolated syndrome |
| Cognitive reserve |
| Comorbidities |
| Complementary treatment |
| Compounded |
| Conditioning regimen |
| Confidence intervals |
| Contraindication |
| Cytokine-release syndrome |
| Cytokines |
| Deconditioning |
| Defusion |
| Demyelinate |
| Demyelinated |
| Demyelination |
| Dephosphorylate |
| De-risk |
| Disease-modifying treatments |
| Dose ̶ response curve |
| Dysgeusia |
| Dyspepsia |
| eCBTI |
| Effector |
| Ejection fraction |
| Electrocardiogram |
| Electrophoresis |
| Eloquent |
| Encephalitis |
| Endogenous |
| End-organ |
| Enhancing lesions |
| Enzyme |
| Epithelial |
| Evoked potential |
| Expanded Disability Status Scale |
| Extended interval dosing |
| Extravasation |
| First-line therapy |
| Focal |
| Gadolinium-enhancing lesion |
| Gd-enhancement |
| Glial cells |
| Glomerulonephritis |
| GnRH agonist |
| Granule cell |
| Grey matter |
| Haematopoietic stem-cell transplantation |
| Haemolytic–uraemic syndrome |
| Half-life |
| Hemodialysis |
| Holistic management |
| Humanised |
| Hyperemesis gravidarum |
| Hyperinsulinaemia |
| Hypertension |
| Hypogammaglobulinaemia |
| Hypotension |
| Immune reconstitution therapy |
| Immune surveillance |
| Immunocompetent |
| Immunocompromised |
| Immunoglobulin |
| Immunomodulatory |
| Immunosenescence |
| Immunosuppression |
| Immunosuppressive |
| Infectious mononucleosis |
| Inflammatory mediators |
| Infusion |
| Infusion reactions |
| Innate immune system |
| Intravenous |
| Ion channel |
| JC virus-seronegative |
| JC virus-seropositive |
| JCV-seronegative |
| JCV-seropositive |
| Lesion |
| Leukocytes |
| Leukopenia |
| Lhermitte’s sign |
| Lipoatrophy |
| Listeria |
| Listeria monocytogenes |
| Listeriosis |
| Lumbar puncture |
| Lymphocytes |
| Lymphopaenia |
| Lysis |
| Magnetic resonance imaging |
| Marginating cells |
| Medical gaslighting |
| Melatonin |
| Modafinil |
| Monoclonal gammopathy |
| Monocyte |
| Monophasic |
| MS neurologist |
| Mucositis |
| MUGA scan |
| Myelin |
| Myelination |
| Myeloablative |
| Myoclonus |
| Necrosis |
| NEDA-3 |
| Nerve processes |
| Network analyses |
| Neural plasticity |
| Neurodegenerative |
| Neurofilament |
| Neurofilament light |
| Neurological reserve |
| Neurologist |
| Neuronal transection |
| Neuropathy |
| Neurophysiological |
| Neuroprotective |
| Neurotropic |
| Neutralising antibodies |
| Neutropenia |
| Neutrophil |
| Nocardia |
| Nocardiosis |
| Nocturia |
| Non-myeloablative |
| Non-selective |
| Normalise |
| Off patent |
| Off-label |
| Off-target side effects |
| Oligoclonal band |
| Oligodendrocyte |
| Oligospermia |
| Opportunistic infections |
| Optic nerve |
| Optic neuritis |
| Orphan disease |
| Over-the-counter |
| Parasympathetic nervous system |
| Parenteral |
| Periodic limb movements of sleep |
| Peripheral |
| Phagocytosis |
| Pharmacogenomics |
| Phase 3 |
| Plasma exchange |
| Platelets |
| Platform therapy |
| Polypharmacy |
| Positive symptom |
| Posterior fossa |
| Posterior reversible encephalopathy syndrome |
| Post-hoc analyses |
| Postprandial hypersomnolence |
| Primary progressive MS |
| Prodrug |
| Prognosis |
| Progressive multifocal leukoencephalopathy |
| Progressive relapsing MS |
| Proinflammatory |
| Prophylactic |
| Prophylaxis |
| Protein |
| Pruritus |
| Pseudolymphoma |
| Pseudotumoral MS |
| Pyrexia |
| Radiologically isolated syndrome |
| Real-life data |
| Rebaseline |
| Rebound activity |
| Relapse |
| Relapsing–remitting MS |
| Remission |
| Remyelinated |
| Reticuloendothelial system |
| S1P modulators |
| Sclerosis |
| Secondary autoimmunity |
| Secondary malignancies |
| Secondary progressive MS |
| Second-line therapy |
| Selective |
| Serology |
| Seronegative |
| Seropositive |
| Serum |
| Single-attack progressive MS |
| Sleep hygiene |
| Smouldering MS |
| Sodium channels |
| Spasticity |
| Subclinical |
| Subcutaneous |
| T cell |
| T1 gadolinium-enhancing lesions |
| T2 |
| T2 lesions |
| Tachycardia |
| Tachyphylaxis |
| Teratogenic |
| Tetrahydrocannabinol |
| Thrombotic thrombocytopenic purpura |
| Thyrotoxicosis |
| Titration |
| Tricyclic |
| Tumefactive |
| Tumefactive MS |
| Uhtoff’s phenomenon |
| Urticaria |
| Vagus nerve |
| VLA-4 |
| White blood cell |
| White matter |
